DOCSLIB.ORG

Association of Warfarin Dose with Genes Involved in Its Action and Metabolism

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Association of Warfarin Dose with Genes Involved in Its Action and Metabolism CORE Metadata, citation and similar papers at core.ac.uk Provided by Springer - Publisher Connector Hum Genet (2007) 121:23–34 DOI 10.1007/s00439-006-0260-8 ORIGINAL INVESTIGATION Association of warfarin dose with genes involved in its action and metabolism Mia Wadelius · Leslie Y. Chen · Niclas Eriksson · Suzannah Bumpstead · Jilur Ghori · Claes Wadelius · David Bentley · Ralph McGinnis · Panos Deloukas Received: 6 July 2006 / Accepted: 1 September 2006 / Published online: 18 October 2006 © Springer-Verlag 2006 Abstract We report an extensive study of variability associated with dose (P < 0.05). VKORC1, CYP2C9, in genes encoding proteins that are believed to be CYP2C18 and CYP2C19 were signiWcant after involved in the action and biotransformation of warfa- experiment-wise correction for multiple testing rin. Warfarin is a commonly prescribed anticoagulant (P < 0.000175), however, the association of CYP2C18 that is diYcult to use because of the wide interindivid- and CYP2C19 was fully explained by linkage disequilib- ual variation in dose requirements, the narrow thera- rium with CYP2C9*2 and/or *3. PROC and APOE peutic range and the risk of serious bleeding. We were both signiWcantly associated with dose after cor- genotyped 201 patients for polymorphisms in 29 genes rection within each gene. A multiple regression model in the warfarin interactive pathways and tested them for with VKORC1, CYP2C9, PROC and the non-genetic association with dose requirement. In our study, poly- predictors age, bodyweight, drug interactions and indi- morphisms in or Xanking the genes VKORC1, CYP2C9, cation for treatment jointly accounted for 62% of vari- CYP2C18, CYP2C19, PROC, APOE, EPHX1, CALU, ance in warfarin dose. Weaker associations observed GGCX and ORM1-ORM2 and haplotypes of for other genes could explain up to »10% additional VKORC1, CYP2C9, CYP2C8, CYP2C19, PROC, F7, dose variance, but require testing and validation in an GGCX, PROZ, F9, NR1I2 and ORM1-ORM2 were independent and larger data set. Translation of this knowledge into clinical guidelines for warfarin prescrip- tion will be likely to have a major impact on the safety Y Electronic supplementary material Supplementary material is and e cacy of warfarin. available in the online version of this article at http://dx.doi.org/ 10.1007/s00439-006-0260-8 and is accessible for authorized users. Abbreviations M. Wadelius ABCB1 ATP-binding cassette transporter B1 Department of Medical Sciences, Clinical Pharmacology, gene, P-glycoprotein gene or MDR1 University Hospital, 751 85 Uppsala, Sweden APOE Apolipoprotein E CALU Calumenin gene L. Y. Chen · S. Bumpstead · J. Ghori · D. Bentley · R. McGinnis · P. Deloukas (&) CAR Constitutive androstane receptor The Wellcome Trust Sanger Institute, CYP1A1 Cytochrome P450 1A1 Wellcome Trust Genome Campus, CYP1A2 Cytochrome P450 1A2 Hinxton, Cambridgeshire, CB10 1SA, UK CYP2A6 Cytochrome P 2A6 e-mail: [email protected] 450 CYP2C18 Cytochrome P450 2C18 N. Eriksson CYP2C19 Cytochrome P450 2C19 UCR—Uppsala Clinical Research Center, CYP2C8 Cytochrome P450 2C8 Uppsala Science Park, 751 83 Uppsala, Sweden CYP2C9 Cytochrome P450 2C9 P C. Wadelius CYP3A4 Cytochrome 450 3A4 Department of Genetics and Pathology, Medical Genetics, CYP3A5 Cytochrome P450 3A5 Rudbeck Laboratory, 751 85 Uppsala, Sweden EPHX1 Epoxide hydrolase 1, microsomal gene 123 24 Hum Genet (2007) 121:23–34 F2 Coagulation factor II gene or prothrom dose requirement, which varies 20-fold, is inXuenced bin gene by factors such as intake of vitamin K, ethnicity, illness, F5 Coagulation factor V gene age, gender, concurrent medication, body mass index F7 Coagulation factor VII gene and genetic factors (Loebstein et al. 2001; Takahashi F9 Coagulation factor IX gene and Echizen 2003; Wadelius et al. 2004). F10 Coagulation factor X gene Warfarin acts through interference with the recy- FII Coagulation factor II or prothrombin cling of vitamin K in the liver, which leads to secretion FIIa Coagulation factor II activated or of inactive vitamin K-dependent proteins (Bell et al. thrombin 1972; Dahlbäck 2005). Figure 1 shows the genes that FIX Coagulation factor IX are believed to be involved in the biotransformation of FIXa Coagulation factor IX activated vitamin K, warfarin and the vitamin K-dependent clot- FV Coagulation factor V ting factors, here called the warfarin interactive path- FVII Coagulation factor VII ways (Supplementary Table S1; for details see FVIIa Coagulation factor VII activated Wadelius and Pirmohamed 2006). The main protein in FX Coagulation factor X the vitamin K epoxide reductase complex is encoded FXa Coagulation factor X activated by VKORC1 (Li et al. 2004; Rost et al. 2004). Common GAS6 Growth-arrest speciWc 6 variation in human VKORC1 is one of the most impor- GGCX Gamma-glutamyl carboxylase gene tant genetic factors determining warfarin dose MDR1 Multidrug resistance gene 1, P-glycopro (D’Andrea et al. 2005; Geisen et al. 2005; Rieder et al. tein gene or ABCB1 2005; Sconce et al. 2005; Wadelius et al. 2005; Veenstra NQO1 NAD(P)H dehydrogenase, et al. 2005; Yuan et al. 2005). Another putative subunit quinone 1 gene of the vitamin K epoxide reductase is the microsomal NR1I2 Pregnane X receptor gene epoxide hydrolase 1, encoded by EPHX1, which har- NR1I3 Constitutive androstane receptor gene bours a vitamin K-epoxide binding site (Cain et al. ORM1 Orosomucoid 1 gene or Alpha-1-acid 1997; Loebstein et al. 2005; Morisseau and Hammock glycoprotein 1 gene 2005). Calumenin, encoded by CALU, binds to vitamin ORM2 Orosomucoid 2 gene or Alpha-1-acid K epoxide reductase and inhibits the eVect of warfarin glycoprotein 2 gene (Wallin et al. 2001; Wajih et al. 2004). PCR Polymerase chain reaction A high intake of the fat-soluble vitamin K1 can PROC Protein C gene reverse the action of warfarin. Vitamin K1 is absorbed PROS1 Protein S gene from the small intestine along with dietary fat, and sub- PROZ Protein Z gene sequently cleared by the liver through an apolipopro- PT INR Prothrombin time international norma tein E (APOE) receptor speciWc uptake (Berkner and lised ratio Runge 2004). The uptake of vitamin K1 into the liver PXR Pregnane X receptor varies between diVerent APOE alleles and is in the SERPINC1 Anti-thrombin III gene order of *E2 <*E3 < *E4 (Saupe et al. 1993; Kohlme- siRNA Small interfering ribonucleic acid ier et al. 1996). It has also been suggested that the anti- SNP Single nucleotide polymorphism oxidant enzyme nicotine adenine dinucleotide UTR Untranslated region phosphate (NAD(P)H) dehydrogenase, encoded by VKORC1 Vitamin K epoxide reductase NQO1, has the potential to reduce dietary vitamin K complex subunit 1 gene (Wallin and Hutson 1982; Berkner and Runge 2004). Reduced vitamin K is the essential cofactor for the activation of vitamin K-dependent proteins by gamma- Background glutamyl carboxylase, encoded by GGCX (Wu et al. 1997; Berkner 2000). The main vitamin K-dependent Warfarin is one of the most widely used coumarin anti- proteins are clotting factors II, VII, IX and X, proteins coagulants in the treatment of atrial Wbrillation, heart C, S and Z, and the growth-arrest speciWc protein 6, valve prosthesis, recurrent stroke, deep vein thrombo- encoded by F2, F7, F9, F10, PROC, PROS1, PROZ sis and pulmonary embolism (Daly and King 2003). and GAS6, respectively (Berkner and Runge 2004). A However, its use is made diYcult by the wide interindi- non-vitamin K-dependent clotting protein anti-thrombin vidual variation in dose required to achieve a therapeu- III, encoded by SERPINC1, inhibits the vitamin K- tic eVect, the narrow therapeutic range, and the risk of dependent factors II, IX and X (Dahlbäck 2005). serious bleeding (Landefeld and Beyth 1993). Warfarin Furthermore, the point mutation Arg506Gln (FV Leiden) 123 Hum Genet (2007) 121:23–34 25 Fig. 1 An overview of the interaction between warfarin and the 29 genes. This path- way illustrates genes thought to mediate the eVects of war- farin. It also depicts a simpli- Wed representation of the biotransformation of warfarin and vitamin K in F5 is a common cause of thromboembolism, and is may be involved in the metabolism of R-warfarin therefore a known cause of warfarin treatment (Larsen (Rettie et al. 1992; Zhang et al. 1995; Kaminsky and et al. 1998). Zhang 1997; Huang et al. 2004). Cytochrome P450 The molecular basis of warfarin pharmacokinetics enzymes are induced by the nuclear hormone receptors has been extensively studied (Sanderson et al. 2005). pregnane X receptor (PXR) and constitutive andro- Warfarin is administered as a racemate that consists of stane receptor (CAR), which are encoded by NR1I2 R- and S-enantiomers, the S-form being 3–5 times and NR1I3 (Lehmann et al. 1998; Chen et al. 2004). more active than the R-form (Rettie et al. 1992). War- Based on an inhibition assay, there is some evidence farin is rapidly absorbed from the stomach and the that transport of warfarin out of the liver and into the upper gastrointestinal tract (Palareti and Legnani bile may be mediated by P-glycoprotein, which 1996), and in the circulating blood it is highly bound to is encoded by ABCB1 (MDR1) (Sussman et al. 2002). albumin and alpha 1-acid glycoproteins, encoded by P-glycoprotein can be induced by the nuclear hormone ORM1 and ORM2 (Otagiri et al. 1987). Once warfarin receptor PXR (Geick et al. 2001). has entered the liver, S-warfarin is metabolised by We and others have shown that common variants in cytochrome P450 2C9 (CYP2C9) (Rettie et al. 1992; the VKORC1 and CYP2C9 genes together with a lim- Kaminsky and Zhang 1997). Patients with CYP2C9 ited subset of environmental determinants account for variant alleles *2 and *3 alleles (http://www.imm.ki.se/ around 50–60% of the variance in warfarin dose CYPalleles/) require lower mean daily warfarin doses requirement (Sconce et al. 2005; Wadelius et al. 2005; than extensive metabolisers homozygous for the *1 Veenstra et al.
Load more

Recommended publications
  • Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid
    Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 231 _____________________________ _____________________________ Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid Cloning, Expression and Catalytic Properties of CYP4F8 and CYP4F21 BY JOHAN BYLUND ACTA UNIVERSITATIS UPSALIENSIS UPPSALA 2000 Dissertation for the Degree of Doctor of Philosophy (Faculty of Pharmacy) in Pharmaceutical Pharmacology presented at Uppsala University in 2000 ABSTRACT Bylund, J. 2000. Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid: Cloning, Expression and Catalytic Properties of CYP4F8 and CYP4F21. Acta Universitatis Upsaliensis. Comprehensive Summaries of Uppsala Dissertations from Faculty of Pharmacy 231 50 pp. Uppsala. ISBN 91-554-4784-8. Cytochrome P450 (P450 or CYP) is an enzyme system involved in the oxygenation of a wide range of endogenous compounds as well as foreign chemicals and drugs. This thesis describes investigations of P450-catalyzed oxygenation of prostaglandins, linoleic and arachidonic acids. The formation of bisallylic hydroxy metabolites of linoleic and arachidonic acids was studied with human recombinant P450s and with human liver microsomes. Several P450 enzymes catalyzed the formation of bisallylic hydroxy metabolites. Inhibition studies and stereochemical analysis of metabolites suggest that the enzyme CYP1A2 may contribute to the biosynthesis of bisallylic hydroxy fatty acid metabolites in adult human liver microsomes. 19R-Hydroxy-PGE and 20-hydroxy-PGE are major components of human and ovine semen, respectively. They are formed in the seminal vesicles, but the mechanism of their biosynthesis is unknown. Reverse transcription-polymerase chain reaction using degenerate primers for mammalian CYP4 family genes, revealed expression of two novel P450 genes in human and ovine seminal vesicles.
    [Show full text]
  • Synonymous Single Nucleotide Polymorphisms in Human Cytochrome
    DMD Fast Forward. Published on February 9, 2009 as doi:10.1124/dmd.108.026047 DMD #26047 TITLE PAGE: A BIOINFORMATICS APPROACH FOR THE PHENOTYPE PREDICTION OF NON- SYNONYMOUS SINGLE NUCLEOTIDE POLYMORPHISMS IN HUMAN CYTOCHROME P450S LIN-LIN WANG, YONG LI, SHU-FENG ZHOU Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing 100191, P. R. China (LL Wang & Y Li) Discipline of Chinese Medicine, School of Health Sciences, RMIT University, Bundoora, Victoria 3083, Australia (LL Wang & SF Zhou). 1 Copyright 2009 by the American Society for Pharmacology and Experimental Therapeutics. DMD #26047 RUNNING TITLE PAGE: a) Running title: Prediction of phenotype of human CYPs. b) Author for correspondence: A/Prof. Shu-Feng Zhou, MD, PhD Discipline of Chinese Medicine, School of Health Sciences, RMIT University, WHO Collaborating Center for Traditional Medicine, Bundoora, Victoria 3083, Australia. Tel: + 61 3 9925 7794; fax: +61 3 9925 7178. Email: [email protected] c) Number of text pages: 21 Number of tables: 10 Number of figures: 2 Number of references: 40 Number of words in Abstract: 249 Number of words in Introduction: 749 Number of words in Discussion: 1459 d) Non-standard abbreviations: CYP, cytochrome P450; nsSNP, non-synonymous single nucleotide polymorphism. 2 DMD #26047 ABSTRACT Non-synonymous single nucleotide polymorphisms (nsSNPs) in coding regions that can lead to amino acid changes may cause alteration of protein function and account for susceptivity to disease. Identification of deleterious nsSNPs from tolerant nsSNPs is important for characterizing the genetic basis of human disease, assessing individual susceptibility to disease, understanding the pathogenesis of disease, identifying molecular targets for drug treatment and conducting individualized pharmacotherapy.
    [Show full text]
  • I Copyright® Ariel R. Topletz, 2013
    Copyright® Ariel R. Topletz, 2013 i The Relative Importance of CYP26A1 and CYP26B1 in Mediating Retinoid Homeostasis: Studies on the Formation, Elimination and Biological Activity of All-trans-Retinoic Acid Metabolites Ariel R. Topletz A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2013 Reading Committee: Nina Isoherranen, Chair Jashvant D Unadkat Joanne Wang Program Authorized to Offer Degree: Department of Pharmaceutics ii University of Washington Abstract Ariel R. Topletz Chair of the Supervisory Committee: Associate Professor Nina Isoherranen Department of Pharmaceutics All-trans-retinoic acid (atRA), the active metabolite of Vitamin A (retinol), is an essential nutrient during both fetal development and adult life. The concentration of atRA within a cell is tightly regulated by the synthesis and elimination of atRA. One of the major elimination pathways for atRA is oxidation, predominantly by the cytochrome P450s CYP26A1 and CYP26B1 that efficiently hydroxylate atRA. The role of both CYP26A1 and CYP26B1 is believed to be to inactivate atRA, and both are essential for correct fetal development. It is not known whether both enzymes play crucial roles during adult life. In this work, the differences in the catalytic efficiency of CYP26A1 and CYP26B1 and the metabolites formed from atRA by CYP26A1 and CYP26B1 were explored. The subsequent metabolism and the activity of atRA metabolites were also evaluated. CYP26A1 was determined to form 4-OH-RA from atRA more efficiently (Km = 50 nM, Clint = 190 µL/min/pmoles P450) than CYP26B1 (Km = 19 nM, Clint = 43 µL/min/pmoles P450). In addition, formation of 4-OH-RA by CYP26A1 was stereoselective resulting in formation of (4S)-OH-RA whereas no significant stereoselectivity in 4-OH-RA formation by CYP26B1was observed.
    [Show full text]
  • The Transcriptomic Landscape of Prostate Cancer Development and Progression: an Integrative Analysis
    cancers Article The Transcriptomic Landscape of Prostate Cancer Development and Progression: An Integrative Analysis Jacek Marzec 1,† , Helen Ross-Adams 1,*,† , Stefano Pirrò 1 , Jun Wang 1 , Yanan Zhu 2, Xueying Mao 2, Emanuela Gadaleta 1 , Amar S. Ahmad 3, Bernard V. North 3, Solène-Florence Kammerer-Jacquet 2, Elzbieta Stankiewicz 2, Sakunthala C. Kudahetti 2, Luis Beltran 4, Guoping Ren 5, Daniel M. Berney 2,4, Yong-Jie Lu 2 and Claude Chelala 1,6,* 1 Bioinformatics Unit, Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK; [email protected] (J.M.); [email protected] (S.P.); [email protected] (J.W.); [email protected] (E.G.) 2 Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK; [email protected] (Y.Z.); [email protected] (X.M.); solenefl[email protected] (S.-F.K.-J.); [email protected] (E.S.); [email protected] (S.C.K.); [email protected] (D.M.B.); [email protected] (Y.-J.L.) 3 Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine, Queen Mary University of London, London EC1M 6BQ, UK; [email protected] (A.S.A.); [email protected] (B.V.N.) 4 Department of Pathology, Barts Health NHS, London E1 F1R, UK; [email protected] 5 Department of Pathology, The First Affiliated Hospital, Zhejiang University Medical College, Hangzhou 310058, China; [email protected] 6 Centre for Computational Biology, Life Sciences Initiative, Queen Mary University London, London EC1M 6BQ, UK * Correspondence: [email protected] (H.R.-A.); [email protected] (C.C.) † These authors contributed equally to this work.
    [Show full text]
  • Simulation of Physicochemical and Pharmacokinetic Properties of Vitamin D3 and Its Natural Derivatives
    pharmaceuticals Article Simulation of Physicochemical and Pharmacokinetic Properties of Vitamin D3 and Its Natural Derivatives Subrata Deb * , Anthony Allen Reeves and Suki Lafortune Department of Pharmaceutical Sciences, College of Pharmacy, Larkin University, Miami, FL 33169, USA; [email protected] (A.A.R.); [email protected] (S.L.) * Correspondence: [email protected] or [email protected]; Tel.: +1-224-310-7870 or +1-305-760-7479 Received: 9 June 2020; Accepted: 20 July 2020; Published: 23 July 2020 Abstract: Vitamin D3 is an endogenous fat-soluble secosteroid, either biosynthesized in human skin or absorbed from diet and health supplements. Multiple hydroxylation reactions in several tissues including liver and small intestine produce different forms of vitamin D3. Low serum vitamin D levels is a global problem which may origin from differential absorption following supplementation. The objective of the present study was to estimate the physicochemical properties, metabolism, transport and pharmacokinetic behavior of vitamin D3 derivatives following oral ingestion. GastroPlus software, which is an in silico mechanistically-constructed simulation tool, was used to simulate the physicochemical and pharmacokinetic behavior for twelve vitamin D3 derivatives. The Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) Predictor and PKPlus modules were employed to derive the relevant parameters from the structural features of the compounds. The majority of the vitamin D3 derivatives are lipophilic (log P values > 5) with poor water solubility which are reflected in the poor predicted bioavailability. The fraction absorbed values for the vitamin D3 derivatives were low except for calcitroic acid, 1,23S,25-trihydroxy-24-oxo-vitamin D3, and (23S,25R)-1,25-dihydroxyvitamin D3-26,23-lactone each being greater than 90% fraction absorbed.
    [Show full text]
  • MOL #76356 1 an Inducible Cytochrome P450 3A4-Dependent
    Molecular Pharmacology Fast Forward. Published on December 28, 2011 as DOI: 10.1124/mol.111.076356 Molecular PharmacologyThis article Fast has not Forward. been copyedited Published and formatted. on TheDecember final version 28, may 2011 differ asfrom doi:10.1124/mol.111.076356 this version. MOL #76356 An Inducible Cytochrome P450 3A4-dependent Vitamin D Catabolic Pathway Zhican Wang, Yvonne S. Lin, Xi Emily Zheng, Tauri Senn, Takanori Hashizume, Michele Scian, Leslie J. Dickmann, Sidney D. Nelson, Thomas A. Baillie, Mary F. Hebert, David Blough, Downloaded from Connie L. Davis, Kenneth E. Thummel molpharm.aspetjournals.org Departments of Pharmaceutics (Z.W, Y.S.L., X.E.Z., T.S., K.E.T.), Medicinal Chemistry (M.S., at ASPET Journals on September 24, 2021 S.D.N, T.A.B.), Pharmacy (M.F.H., D.B.), and Division of Nephrology (C.L.D.), University of Washington, Seattle, WA, USA; Pharmacokinetics Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd, Japan (T.H.); Biochemistry and Biophysics Group, Department of Pharmacokinetics and Drug Metabolism, Amgen, Seattle, WA, USA (L.J.D). 1 Copyright 2011 by the American Society for Pharmacology and Experimental Therapeutics. Molecular Pharmacology Fast Forward. Published on December 28, 2011 as DOI: 10.1124/mol.111.076356 This article has not been copyedited and formatted. The final version may differ from this version. MOL #76356 Running Title Page Running title: Metabolism of 25-hydroxyvitamin D3 by CYP3A4 Corresponding author: Kenneth Thummel, Ph.D. Department of Pharmaceutics, Box 357610
    [Show full text]
  • Robert Foti to Cite This Version
    Characterization of xenobiotic substrates and inhibitors of CYP26A1, CYP26B1 and CYP26C1 using computational modeling and in vitro analyses Robert Foti To cite this version: Robert Foti. Characterization of xenobiotic substrates and inhibitors of CYP26A1, CYP26B1 and CYP26C1 using computational modeling and in vitro analyses. Agricultural sciences. Université Nice Sophia Antipolis, 2016. English. NNT : 2016NICE4033. tel-01376678 HAL Id: tel-01376678 https://tel.archives-ouvertes.fr/tel-01376678 Submitted on 5 Oct 2016 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Université de Nice-Sophia Antipolis Thèse pour obtenir le grade de DOCTEUR DE L’UNIVERSITE NICE SOPHIA ANTIPOLIS Spécialité : Interactions Moléculaires et Cellulaires Ecole Doctorale : Sciences de la Vie et de la Santé (SVS) Caractérisation des substrats xénobiotiques et des inhibiteurs des cytochromes CYP26A1, CYP26B1 et CYP26C1 par modélisation moléculaire et études in vitro présentée et soutenue publiquement par Robert S. Foti Le 4 Juillet 2016 Membres du jury Dr. Danièle Werck-Reichhart Rapporteur Dr. Philippe Roche Rapporteur Pr. Serge Antonczak Examinateur Dr. Philippe Breton Examinateur Pr. Philippe Diaz Examinateur Dr. Dominique Douguet Directrice de thèse 1 1. Table of Contents 1. Table of Contents ..............................................................................................................................
    [Show full text]
  • Recent Advances in P450 Research
    The Pharmacogenomics Journal (2001) 1, 178–186 2001 Nature Publishing Group All rights reserved 1470-269X/01 $15.00 www.nature.com/tpj REVIEW Recent advances in P450 research JL Raucy1,2 ABSTRACT SW Allen1,2 P450 enzymes comprise a superfamily of heme-containing proteins that cata- lyze oxidative metabolism of structurally diverse chemicals. Over the past few 1La Jolla Institute for Molecular Medicine, San years, there has been significant progress in P450 research on many fronts Diego, CA 92121, USA; 2Puracyp Inc, San and the information gained is currently being applied to both drug develop- Diego, CA 92121, USA ment and clinical practice. Recently, a major accomplishment occurred when the structure of a mammalian P450 was determined by crystallography. Correspondence: Results from these studies will have a major impact on understanding struc- JL Raucy,La Jolla Institute for Molecular Medicine,4570 Executive Dr,Suite 208, ture-activity relationships of P450 enzymes and promote prediction of drug San Diego,CA 92121,USA interactions. In addition, new technologies have facilitated the identification Tel: +1 858 587 8788 ext 116 of several new P450 alleles. This information will profoundly affect our under- Fax: +1 858 587 6742 E-mail: jraucyȰljimm.org standing of the causes attributed to interindividual variations in drug responses and link these differences to efficacy or toxicity of many thera- peutic agents. Finally, the recent accomplishments towards constructing P450 null animals have afforded determination of the role of these enzymes in toxicity. Moreover, advances have been made towards the construction of humanized transgenic animals and plants. Overall, the outcome of recent developments in the P450 arena will be safer and more efficient drug ther- apies.
    [Show full text]
  • Pharmacogenetics of Cytochrome P450 and Its Application and Value in Drug Therapy – the Past, Present and Future
    Pharmacogenetics of cytochrome P450 and its application and value in drug therapy – the past, present and future Magnus Ingelman-Sundberg Karolinska Institutet, Stockholm, Sweden The human genome x 3,120,000,000 nucleotides x 23,000 genes x >100 000 transcripts (!) x up to 100,000 aa differences between two proteomes x 10,000,000 SNPs in databases today The majority of the human genome is transcribed and has an unknown function RIKEN consortium Science 7 Sep 2005 Interindividual variability in drug action Ingelman-Sundberg, M., J Int Med 250: 186-200, 2001, CYP dependent metabolism of drugs (80 % of all phase I metabolism of drugs) Tolbutamide Beta blokers Warfarin Antidepressants Phenytoin CYP2C9* Diazepam Antipsychotics NSAID Citalopram Dextromethorphan CYP2D6* CYP2C19* Anti ulcer drugs Codeine CYP2E1 Clozapine Debrisoquine CYP1A2 Ropivacaine CYP2B6* Efavirenz Cyclophosphamide CYP3A4/5/7 Cyclosporin Taxol Tamoxifen Tacrolimus 40 % of the phase I Amprenavir Amiodarone metabolism is Cerivastatin carried out by Erythromycin polymorphic P450s Methadone Quinine (enzymes in Italics) Phenotypes and mutations PM, poor metabolizers; IM, intermediate met; EM, efficient met; UM, ultrarapid met Frequency Population Homozygous based dosing for • Stop codons • Heterozygous Two funct deleterious • Deletions alleles SNPs • Deleterious • Gene missense • Unstable duplication SNPs protein • Induction • Splice defects EM PM IM UM Enzyme activity/clearance The Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee http://www.imm.ki.se/CYPalleles/ Webmaster: Sarah C Sim Editors: Magnus Ingelman-Sundberg, Ann K. Daly, Daniel W. Nebert Advisory Board: Jürgen Brockmöller, Michel Eichelbaum, Seymour Garte, Joyce A. Goldstein, Frank J. Gonzalez, Fred F. Kadlubar, Tetsuya Kamataki, Urs A.
    [Show full text]
  • Regulation of Cytochrome P450 (CYP) Genes by Nuclear Receptors Paavo HONKAKOSKI*1 and Masahiko NEGISHI† *Department of Pharmaceutics, University of Kuopio, P
    Biochem. J. (2000) 347, 321–337 (Printed in Great Britain) 321 REVIEW ARTICLE Regulation of cytochrome P450 (CYP) genes by nuclear receptors Paavo HONKAKOSKI*1 and Masahiko NEGISHI† *Department of Pharmaceutics, University of Kuopio, P. O. Box 1627, FIN-70211 Kuopio, Finland, and †Pharmacogenetics Section, Laboratory of Reproductive and Developmental Toxicology, NIEHS, National Institutes of Health, Research Triangle Park, NC 27709, U.S.A. Members of the nuclear-receptor superfamily mediate crucial homoeostasis. This review summarizes recent findings that in- physiological functions by regulating the synthesis of their target dicate that major classes of CYP genes are selectively regulated genes. Nuclear receptors are usually activated by ligand binding. by certain ligand-activated nuclear receptors, thus creating tightly Cytochrome P450 (CYP) isoforms often catalyse both formation controlled networks. and degradation of these ligands. CYPs also metabolize many exogenous compounds, some of which may act as activators of Key words: endobiotic metabolism, gene expression, gene tran- nuclear receptors and disruptors of endocrine and cellular scription, ligand-activated, xenobiotic metabolism. INTRODUCTION sex-, tissue- and development-specific expression patterns which are controlled by hormones or growth factors [16], suggesting Overview of the cytochrome P450 (CYP) superfamily that these CYPs may have critical roles, not only in elimination CYPs constitute a superfamily of haem-thiolate proteins present of endobiotic signalling molecules, but also in their production in prokaryotes and throughout the eukaryotes. CYPs act as [17]. Data from CYP gene disruptions and natural mutations mono-oxygenases, with functions ranging from the synthesis and support this view (see e.g. [18,19]). degradation of endogenous steroid hormones, vitamins and fatty Other mammalian CYPs have a prominent role in biosynthetic acid derivatives (‘endobiotics’) to the metabolism of foreign pathways.
    [Show full text]
  • Inhibition of Cytochrome P450 Enzymes
    7 Inhibition of Cytochrome P450 Enzymes Maria Almira Correia and Paul R. Ortiz de Monteflano 1. Introduction of P450 inhibitors are available in various reviews"^^^. This chapter focuses on the mecha­ Three steps in the catalytic cycle of nisms of inactivation; thus, most of the chapter is cytochrome P450 (P450, CYP; see Chapters 5 and devoted to the discussion of agents that require 6) are particularly vulnerable to inhibition: (a) the P450 catalysis to fiilfill their inhibitory potential. binding of substrates, (b) the binding of molecular The mechanisms of reversible competitive and oxygen subsequent to the first electron transfer, noncompetitive inhibitors, despite their practical and (c) the catalytic step in which the substrate is importance, are relatively straightforward and are actually oxidized. Only inhibitors that act at one of discussed more briefly. these three steps will be considered in this chapter. Inhibitors that act at other steps in the catalytic cycle, such as agents that interfere with the 2. Reversible Inhibitors electron supply to the hemoprotein by accepting electrons directly from P450 reductase^"^, are not Reversible inhibitors compete with substrates discussed here. for occupancy of the active site and include agents P450 inhibitors can be divided into three that (a) bind to hydrophobic regions of the active mechanistically distinct classes: Agents that site, (b) coordinate to the heme iron atom, or (a) bind reversibly, (b) form quasi-irreversible (c) enter into specific hydrogen bonding or ionic complexes with the heme iron atom, and (c) bind interactions with active-site residues"*"^^. The first irreversibly to the protein or the heme moiety, or mechanism, in which the inhibitor simply competes accelerate the degradation and/or oxidative frag­ for binding to lipophilic domains of the active site, mentation of the prosthetic heme.
    [Show full text]
  • Profiling Cytochrome P450 Expression in Ovarian Cancer: Identification of Prognostic Markers Diane Downie,1Morag C.E
    Imaging, Diagnosis, Prognosis Profiling Cytochrome P450 Expression in Ovarian Cancer: Identification of Prognostic Markers Diane Downie,1Morag C.E. McFadyen,1Patrick H. Rooney,1, 3 Margaret E. Cruickshank,2 David E. Parkin,2 Iain D. Miller,1Colin Telfer,3 William T. Melvin,3 and Graeme I. Murray1 Abstract Purpose: The cytochromes P450 are a multigene family of enzymes with a central role in the oxidative metabolism of a wide range of xenobiotics, including anticancer drugs and biologically active endogenous compounds. The purpose of this study was to define the cytochrome P450 profile of ovarian cancer and identify novel therapeutic targets and establish the prognostic signif- icance of expression of individualcytochrome P450s in this type of cancer. Experimental Design: Immunohistochemistry for a panelof 23 cytochrome P450s and cyto- chrome P450 reductase was done on an ovarian cancer tissue microarray consisting of 99primary epithelialovarian cancers, 22 peritonealmetastasis, and 13 normalovarian samples.The intensity of immunoreactivity in each sample was established by light microscopy. Results: In primary ovarian cancer, several P450s (CYP1B1, CYP2A/2B, CYP2F1, CYP2R1, CYP2U1,CYP3A5, CYP3A7,CYP3A43, CYP4Z1,CYP26A1,and CYP51)were present at a signif- icantlyhigher levelof intensity compared with normalovary. P450 expression was alsodetected in ovarian cancer metastasis and CYP2S1and P450 reductase both showed significantly in- creased expression in metastasis compared with primary ovarian cancer. The presence of low/ negative CYP2A/2B (log rank = 7.06, P = 0.008) or positive CYP4Z1 (log rank = 6.19, P =0.01) immunoreactivity in primary ovarian cancer were each associated with poor prognosis. Both CYP2A/2B and CYP4Z1were also independent markers of prognosis.
    [Show full text]